Oct 13 (Reuters) - Mesoblast Ltd MSB.AX :
* RANDOMIZED CONTROLLED PHASE 3 TRIAL OF REMESTEMCEL-L FOR REDUCED MORTALITY IN COVID-19 ACUTE RESPIRATORY DISTRESS SYNDROME SURPASSES 50% ENROLLMENT
* MESOBLAST LTD - DSMB WILL PERFORM A SECOND INTERIM ANALYSIS IN EARLY NOVEMBER WHEN 45% OF ENROLLMENT TARGET HAS COMPLETED 30 DAYS OF FOLLOW-UP
* MESOBLAST - TRIAL'S PRIMARY ENDPOINT IS REDUCTION IN 30-DAY MORTALITY RELATIVE TO MAXIMAL CARE. ARDS CONTINUES TO BE PRIMARY CAUSE OF DEATH IN COVID19